Inhibitory activity of Bifidobacterium adolescent and cisplatin on the growth of melanoma in mice and its regulatory mechenism

Hong-Ying HUANG,Guang-Chao LIU,Yi-Jun QI,Yao-Wu DU,Yuan-Fang MA

DOI: https://doi.org/10.3321/j.issn:1000-2790.2007.21.008

2007-01-01

Abstract:AIM:To study the inhibitory activity of Bifidobacterium adolescent and cisplatin on the growth of melanoma (B16) in mice and its regulatory mechanism. METHODS: B16 cells were injected to C57/65 mice to establish animal model bearing melanoma. Bifidobacterium adolescent and cisplatin were injected subcutaneously and intraperitoneally respectively. The rates of inhibitory activity on the growth of melanoma (B16) were calculated. Pathological changes of the tumor, tissue and cells were observed by HE staining. B16 cell cycles were determined by flow cytometry. Lymphocytes proliferation was measured by MTT colo-rimetric assay. T-cell subsets were monitored by double labelled fluorescence. RESULTS: The rate of inhibitory activity on the growth of melanoma (B16) by injecting bifidobacterium of 1×1010 cfu/L reached 54%, similar with that in cisplatin group. The inhibitory activity was most strong after bifidobacterium was combined with cisplatin, with the inhibition rate reached 74.45%. Bifidobacterium treatment inhibited proliferation of B16 cells and enhanced the killing activity of cisplatin on B16 cells. Flow cytometry revealed that the B16 cells proliferation was inhibited to G1 stages after bifidobacterium treatment, and to S stages after cisplatin treatment. T-cell immune activity was enhanced after bifidobacterium treatment, which was featured by the increased CD4+ ratio, and the difference was significant compared with the normal group (P<0.01). CONCLUSION: Combination of bifidobacterium with cisplatin exerts strong inhibitory activity on the growth of melanoma. The mechanism is correlated to the inhibitory activity on B16 cell proliferation and the enhanced immune activity in mice.